Epigenetic Changes as Prognostic Markers in Patients With Early Stage Non-Small Cell Lung Cancer
- Evaluate aberrant methylation patterns in tissue and serum samples from patients with
early-stage non-small cell lung cancer (NSCLC) to validate the Johns Hopkins single
- Attempt to define subgroups of patients at greater risk for recurrent or metastatic
disease who may benefit from more aggressive adjuvant therapeutic regimens.
- Develop prognostic indicators for disease-specific and overall survival.
- Define new potential molecular targets for therapy.
OUTLINE: Archived tumor and intrathoracic lymph node tissue samples are analyzed for
aberrant DNA methylation (p16/CDKN2A, DAP kinase, H-cadherin, APC, and RASSF1A) by
methylation-specific PCR. Analyses are then compared with the preliminary data from the
Johns Hopkins institutional study.
Aberrant DNA methylation patterns
Malcolm V. Brock, MD
Sidney Kimmel Comprehensive Cancer Center